Omvoh Approved for Moderately to Severely Active Crohn Disease

What To Know

The FDA approved Omvoh (mirikizumab‑mrkz) for adults with moderately to severely active Crohn disease based on phase 3 VIVID‑1 trial data showing higher rates of clinical remission and endoscopic response versus placebo at week 52.

The article reports dosing used in the trial (IV induction then SC maintenance) and lists common adverse reactions such as upper respiratory infections, injection‑site reactions, headache, arthralgia, and elevated liver tests.

The approval applies to adults who had an inadequate response, loss of response, or intolerance to corticosteroids, immunomodulators, and/or biologics; the article also notes mirikizumab is already indicated for moderately to severely active ulcerative colitis.

Ongoing open‑label extension VIVID‑2 will evaluate longer‑term safety and efficacy for up to 3 years. If you’re reading this because you or a loved one has Crohn disease, this means there is now an additional FDA‑approved IL‑23 p19 inhibitor option that showed benefit on both symptoms and endoscopy in a large phase 3 trial.

Decisions about using mirikizumab should be made with your gastroenterologist and consider prior treatments, medical history, and monitoring needs. For more detail, see the FDA announcement and the Omvoh prescribing information linked in the article.